UK markets open in 2 hours 21 minutes
  • NIKKEI 225

    28,897.38
    +13.25 (+0.05%)
     
  • HANG SENG

    28,721.85
    +412.09 (+1.46%)
     
  • CRUDE OIL

    73.08
    +0.02 (+0.03%)
     
  • GOLD FUTURES

    1,782.10
    +4.70 (+0.26%)
     
  • DOW

    33,945.58
    +68.61 (+0.20%)
     
  • BTC-GBP

    24,384.06
    +622.67 (+2.62%)
     
  • CMC Crypto 200

    813.09
    +18.76 (+2.36%)
     
  • ^IXIC

    14,253.27
    +111.79 (+0.79%)
     
  • ^FTAS

    4,046.87
    +19.91 (+0.49%)
     

BRIEF-Morphosys, I-Mab Sign Agreement For Morphosys's Novel Immuno-Oncology Agent MOR210

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Nov 16 (Reuters) - MorphoSys AG:

* DGAP-NEWS: MORPHOSYS AND I-MAB SIGN STRATEGIC PARTNERING AGREEMENT FOR MORPHOSYS'S NOVEL IMMUNO-ONCOLOGY AGENT MOR210

* MORPHOSYS -UNDER TERMS OF AGREEMENT, I-MAB WILL EXERCISE ITS EXCLUSIVE LICENSE RIGHTS FOR DEVELOPMENT, COMMERCIALIZATION OF MOR210 IN ITS TERRITORIES

* MORPHOSYS WILL RECEIVE AN UPFRONT PAYMENT OF $3.5 MILLION FROM I-MAB

* MORPHOSYS- I-MAB TO HAVE EXCLUSIVE RIGHTS TO DEVELOP, COMMERCIALIZE MOR210 IN CHINA, HONG KONG, MACAO, TAIWAN, SOUTH KOREA Source text for Eikon: Further company coverage:

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting